Investing.com - Deutsche Bank upgraded Qiagen NV (NYSE:QGEN) to Buy from Hold and maintained its price target of $54.00. The firm noted that Qiagen’s shares have fallen almost 30% since late January’s ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Qiagen’s outgoing chief executive Thierry Bernard, M.D., told investors the company does not “comment on rumors” as takeover talks swirl around the diagnostics specialist. Buyout speculation has been ...
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN also to ...
Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Wednesday, 2026-02-04. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will report ...
Shares of Qiagen (NYSE: QGEN) this past week returned to trading in the $50 per-share range after three years mostly lumbering between the high $30s and mid $40s. Investors flocked back to the stock ...
German life sciences tools company Qiagen N.V. (NYSE: QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges. The European molecular ...
Jan 20 (Reuters) - Qiagen (QIA.DE), opens new tab is weighing strategic options, including a potential sale of the diagnostics firm amid fresh takeover interest, Bloomberg News reported on Tuesday, ...
Qiagen NV, the European molecular testing firm, is weighing strategic options including a potential sale amid fresh takeover interest, people with knowledge of the matter said. The company is working ...
A logo of a testing company Qiagen is seen in Hilden, Germany, September 8, 2020. REUTERS/Leon Kuegeler Jan 20 (Reuters) - Qiagen is weighing strategic options, including a potential sale of the ...
Parse Biosciences co-founders are CTO Charles Roco and CEO Alex Rosenberg. (Parse Photo) Seattle’s Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results